with histomorphometric parameters such as bone volume fraction (r = −0.89, p < 0.0001; r = −0.5, p < 0.007; respectively) and trabecular number (r = −0.71, p < 0.0001; r = −0.38, p < 0.037; respectively). Conclusions: These findings demonstrate that the low-dose MIA rat model closely mimics the pathological features of progressive human OA such as cartilage degradation, subchondral bone sclerosis, cyst and osteophyte formation. Moreover, this model demonstrates measurable changes in both the cartilage and the subchondral bone. Monitoring of low-dose MIA induced OA in rats using in vivo micro-CT enables tracking of structural changes in the tibial subchondral bone for the individual animal over time, and could be used to track changes in bone in preclinical drug intervention studies for treatment of OA. Purpose: A homozygous recessive disorder in humans called BardetBiedl Syndrome (BBS) results in primary cilia defects. BBS mutant mice similarly exhibit ciliopathy related disorders. Chondrocytes are known to contain primary cilia. Primary cilia have been shown to play fundamental cellular roles. In the present study we analyzed the temporomandibular (TM) and knee joints of BBS mutant mice as a normal collagen chondrocyte specific animal model of osteoarthritis (OA) in humans. Methods: BBS mutant mice, and age-matched controls, were compared histologically at 3, 6 and 12 months of age. Tissues were fixed in 4% paraformaldehyde, processed to paraffin sections, stained with Hemotoxylin, Safranin O and Fast Green, and analyzed using light microscopy. Joint morphology was characterized and compared using ImageJ (NIH; Bethesda, MD). Sections were stained for HtrA1 and DDR2.
Conclusions: These findings demonstrate that the low-dose MIA rat model closely mimics the pathological features of progressive human OA such as cartilage degradation, subchondral bone sclerosis, cyst and osteophyte formation. Moreover, this model demonstrates measurable changes in both the cartilage and the subchondral bone. Monitoring of low-dose MIA induced OA in rats using in vivo micro-CT enables tracking of structural changes in the tibial subchondral bone for the individual animal over time, and could be used to track changes in bone in preclinical drug intervention studies for treatment of OA. Purpose: A homozygous recessive disorder in humans called BardetBiedl Syndrome (BBS) results in primary cilia defects. BBS mutant mice similarly exhibit ciliopathy related disorders. Chondrocytes are known to contain primary cilia. Primary cilia have been shown to play fundamental cellular roles. In the present study we analyzed the temporomandibular (TM) and knee joints of BBS mutant mice as a normal collagen chondrocyte specific animal model of osteoarthritis (OA) in humans. Methods: BBS mutant mice, and age-matched controls, were compared histologically at 3, 6 and 12 months of age. Tissues were fixed in 4% paraformaldehyde, processed to paraffin sections, stained with Hemotoxylin, Safranin O and Fast Green, and analyzed using light microscopy. Joint morphology was characterized and compared using ImageJ (NIH; Bethesda, MD). Sections were stained for HtrA1 and DDR2.
Results: BBS mutant mice demonstrated evidence of OA including articular cartilage (AC) fissuring, thinning, decrease in proteoglycan saturation with a concomitant increase in HtrA1 and DDR2. Chondrocytes exhibited a propensity for clustering within the matrix. The extent of OA related abnormalities was more pronounced in TM versus knee joints. Conclusions: These results suggest a mechanism of early onset OA in TMJ and knees of BBS mutant mice. The degradation pattern of the articular cartilage, including up regulation of HtrA1 and DDR2, in the TMJ and knees of BBS mutant mice follows the same recognized process that has been observed in mutant collagen OA mouse models. The exacerbated condition of the TMJ compared to knee might indicate that TMJ AC is unique. The present study shows the relevance of the BBS homozygous mouse as a viable alternative model for the human condition of OA. The mucopolysaccharidoses (MPS) are a group of 11 distinct inherited disorders due to mutations in the genes encoding enzymes of glycosaminoglycan (GAG) degradation. Progressive and severe bone and cartilage pathology are characteristic of these disorders. Naturally occurring animal models have been described for several MPS, with similarly severe cartilage and bone disease. The goal of this study was to determine the inflammatory and cartilage/bone changes in the rat model of MPS type VI (Maroteaux-Lamy disease), and to study of the effects of anti-TNF-alpha drugs on the disease progression. Methods: The age-progressive cartilage and bone disease in MPS VI and control rats were studied by a variety of standard biochemical, histological and clinical methods. MPS VI rats also were treated with the anti-TNF-alpha drug, CTNO1081, and the effects on cartilage and bone disease evaluated. Results: The pathological and biochemical changes in the MPS VI rats were very similar to those reported previously in patients with arthritis and induced animal models of the disease. These included elevation of various inflammatory markers, including TNFalpha, enhanced chondrocyte apoptosis, synovial hyperplasia, and proteoglycan degradation. We therefore treated these animals with the experimental anti-TNF-alpha drug, CTNO181. When initiated at 1 month of age, intravenous treatment with CNTO1081 prevented the elevation of TNF-alpha, RANKL and other inflammatory molecules, not only in the blood, but also in articular chondrocytes and fibroblast-like synoviocytes (FLS). Treatment of 6 month-old animals also reduced the levels of these molecules to normal. The number of apoptotic articular chondrocytes in MPS VI rats was similarly reduced, with less infiltration of synovial tissue into the underlying bone. Conclusions: Many of the inflammatory and cartilage/chondrocyte pathological changes that occurred in the MPS VI rats resembled those
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